RF (Radiofrequency) "treatment of choice" for child bone tumours:
This article was originally published in Clinica
Radiofrequency (RF) ablation should be considered the "treatment of choice" for benign bone tumours called osteoid osteomas, according to a study in this month's Radiology. Researchers at Massachusetts General Hospital in Boston, US, followed 263 patients over an 11-year period and found that symptoms were completely relieved in 89% of cases. Usually found in the lower extremities of children and young adults, the tumours are typically removed via surgical excision. RF ablation is less invasive and can be done as an outpatient procedure.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.